Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus (Q33785128)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus |
scientific article |
Statements
1 reference
Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus (English)
1 reference
Timothy P Reilly
1 reference
Michael J Graziano
1 reference
Evan B Janovitz
1 reference
Thomas E Dorr
1 reference
Craig Fairchild
1 reference
Francis Lee
1 reference
Jian Chen
1 reference
Tai Wong
1 reference
Jean M Whaley
1 reference
Mark Tirmenstein
1 reference
29 January 2014
1 reference
1 reference
29 January 2014
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference